Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Active, not recruiting · NCT02610582 · Registry updated 2024-04-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia | Eye Diseases, Hereditary, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, achromatopsia, color vision disorder, cone dystrophy, eye disorder, nervous system disorder, vision disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-04-18 | NCT02610582 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ludwig-Maximilians - University of Munich | 67 |
| STZ eyetrial | 2 |
| University Hospital Tuebingen | 123 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University Hospital Tuebingen, Center for Ophthalmology | Tübingen | Germany | 1 |